天主教聖馬爾定醫院

子宮頸癌化療處方集

最初出版日期:95.03
最後更新日期:115.02

癌別：子宮頸癌		
CCRT	最近改版日期	115.02
	處方內容	(1) Cisplatin 30 mg/ m^2 or 40 mg/ m^2 N/S 500 ml, ≥ 4hrs) / wk (JCO Nov.1996 pp 2901-7) (for CCRT only) (2)~(4) combined with R/T (2) Cisplatin 60 mg/m^2 (N/S 500 ml; ≥ 4hrs) + Epirubicin 50 mg/m^2 (N/S 100 ml; 30 mins) + 5-FU 1500 mg/m^2 (N/S 500 ml; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 ml; ≥ 4hrs) q 4wks (JCO 1987;10:1621-3) (3) (A) ↔ (B) q 2wks (for poor performance &無法住院) (A) Cisplatin 60 mg /m^2 + 5-FU 1000 mg/m^2 (N/S 500 ml; ≥ 3hrs) + Leucovorin 100 mg (N/S 500 ml; ≥3hrs) (B) Epirubicin 50 mg/m^2 + 5-FU 1000 mg/m^2 + Leucovorin 100 mg (4) Cisplatin 60 mg/m^2 +Bleomycin 8 mg/m^2 (N/S 100 ml; 30 mins)+MTX 100 mg/m^2 (N/S 100 ml;1 hr) q 4wks (Am J. Clin. Oncol. 1986;9:12-14)

癌別：子宮頸癌		
Adjuvant	最近改版日期	115.02
	處方內容	(1) Cisplatin 60 mg/m^2 (N/S 500 ml; ≥ 4hrs) + Epirubicin 50 mg/m^2 (N/S 100 ml; 30 mins) + 5-FU 1500 mg/m^2 (N/S 500 ml; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 ml; ≥ 4hrs) q 4wks VI (JCO 1987;10:1621-3) (2) (A) ↔ (B) q 2wks VI (for poor performance &無法住院) (A) Cisplatin 60 mg /m^2 + 5-FU 1000 mg/m^2 (N/S 500 ml; ≥ 3hrs) + Leucovorin 100 mg (N/S 500 ml; ≥3hrs) (B) Epirubicin 50 mg/m^2 + 5-FU 1000 mg/m^2 + Leucovorin 100 mg (3) Cisplatin 60 mg/m^2 +Bleomycin 8 mg/m^2 (N/S 100 ml; 30 mins)+MTX 100 mg/m^2 (N/S 100 ml;1 hr) q 4wks VI (Am J. Clin. Oncol. 1986;9:12-14)
Palliative	最近改版日期	115.02
	處方內容	(1) Cisplatin 60 mg/m^2 (N/S 500 ml; ≥ 4hrs) + Epirubicin 50 mg/m^2 (N/S 100 ml; 30 mins) + 5-FU 1500 mg/m^2 (N/S 500 ml; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 ml; ≥ 4hrs) q 4wks (JCO 1987;10:1621-3) (2) (A) ↔ (B) q 2wks (for poor performance & 無法住院) (A) Cisplatin 60 mg /m^2 + 5-FU 1000 mg/m^2 (N/S 500 ml; ≥ 3hrs) + Leucovorin 100 mg (N/S 500 ml; ≥3hrs) (B) Epirubicin 50 mg/m^2 + 5-FU 1000 mg/m^2 + Leucovorin 100 mg (3) Cisplatin 60 mg/m^2 +Bleomycin 8 mg/m^2 (N/S 100 ml; 30 mins)+MTX 100 mg/m^2 (N/S 100 ml;1 hr) q 4wks(Am J. Clin. Oncol. 1986;9:12-14) (4) Cisplatin 60 mg /m^2 + Topotecan 1 or 1.2 mg/ m^2/d (N/S 100 ml, 30 mins) * 3-5 days q 28d (98/11/1 健保條例 9.16.1：for stage IVB only 且無法手術 or R/T)(Gynecologic Oncology Vol.85 Apr.2002 ; pp89-94)

癌別：子宮頸癌		
Palliative	最近改版日期	115.02
	處方內容	(5) Bevacizumab 5mg/kg (N/S 100ml, 20 mins) q 2wks + one of the following(109/6/1、113/3/1 健保條例 9.37) (i) Paclitaxal 85mg/ m^2 (N/S 500ml, 3 hrs) q 2wks + Cisplatin 60 mg /m^2 (500ml, 24 hrs) q 4wks (Lanut Oncol 2017; 390 (10103): 1054-1663) (ii) Topotecan 0.75mg/m^2 on D1-D3(N/S 100 ml, 30 mins) q 4wks Paclitaxal 85mg/ m^2 (N/S 500ml, 3 hrs) q 2wks (N Engl.J Med. 2014; 385: (8) 734-43) (6) Immunotherapy(自費)： (i) Pembrolizumab 200mg (N/S 100 ml, 60 mins) q 3wks (N Engl Med 2021; 385: 1856-1857) (ii) Nivolumab 3mg/kg (N/S 100 ml, 60 mins) q 2wks ± Ipilumumab 1mg/kg q 6wks (Lancet Oncol. 2024; May. P588-602)